Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease

Neurological Sciences

Volumn 37, Issue 9, 2016, Pages 1403-1435

  Kulshreshtha, Akanksha ^a   Piplani, Poonam ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alzheimer s; Amyloid plaques; Cognition; Disease modifying; Hallmarks; Pharmacotherapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APIGENIN; AVAGACESTAT; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; CHOLINE ACETYLTRANSFERASE; DONEPEZIL; EPIGALLOCATECHIN GALLATE; FLAVONOID; FLURBIPROFEN; FUROCOUMARIN; GALANTAMINE; HARMINE; HOMOTAURINE; HYMENIALDISINE; KAEMPFEROL; LITHIUM; MEMANTINE; METHYLENE BLUE; MORIN; MYRICETIN; PENTOSALEN; QUERCETIN; RIVASTIGMINE; SEMAGACESTAT; STATINE DERIVATIVE; TACRINE; TARENFLURBIL; ACETYLCHOLINESTERASE; AMYLOID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ACTIVE IMMUNOTHERAPY; ALZHEIMER DISEASE; AMYLOID PLAQUE; CALCIUM CELL LEVEL; CELL LOSS; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; ENZYME INHIBITION; HUMAN; LONG TERM POTENTIATION; MEDICINAL PLANT; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHARMACEUTICAL CARE; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; BIOLOGICAL MODEL; CHEMISTRY; COGNITION DISORDERS; COMPLICATION; IMMUNOLOGY; MEMORY DISORDERS; METABOLISM;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; MEMORY DISORDERS; MODELS, BIOLOGICAL; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84973130761     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-016-2625-7     Document Type: Review

References (206)

1. National Institute of Health. MedlinePlus: Alzheimer’s disease. http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html. Accessed 10 Nov 2015
2. National Institute on Aging. Alzheimer’s Disease Education and Referral Center. Alzheimer’s Disease Fact Sheet. http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet. Accessed 10 Nov 2015
3. Alzheimer’s Disease Education and Referral Center. About Alzheimer’s disease: Alzheimer’s basics. https://www.nia.nih.gov/alzheimers/topics/alzheimers-basics. Accessed 10 Nov 2015
4. NIH Senior Health. Alzheimer’s disease. http://nihseniorhealth.gov/alzheimersdisease/whatisalzheimersdisease/01.html. Accessed 14 Nov 2015
5. 2015 Alzheimer’s disease facts and figures. http://www.alz.org/facts/. Accessed 14 Nov 2015
6. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P et al (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 52:1158–1165
7. Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56:484–546
8. Herrmann N, Chau SA, Kircanski I, Lanctot KL (2011) Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs 71:2031–2065
9. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA (2014) Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 1019:1–4
10. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247–265
11. Drachman D (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27:783–790
12. Drachman D, Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30:113–121
13. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237–1239
14. Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thomason K, Mellow AM et al (1988) The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 45:906–912
15. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI et al (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 327:1253–1259
16. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147
17. Davis KL, Mohs RC, Marin D (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281:1401–1406
18. Davies P (1999) Challenging the cholinergic hypothesis in Alzheimer disease. JAMA 281:1433–1434
19. Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E et al (2000) Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of meynert. Acta Neuropathol 100:259–269
20. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophicmolecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4:340–350
21. Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ et al (1992) Convergent cholinergic activities in aging and Alzheimer’s disease. Neurobiol Aging 13:393–400
22. Contestabile A (2011) The history of the cholinergic hypothesis. Behav Brain Res 221:334–340
23. Arendt T, Bigl V, Arendt A, Tennstedt A (1983) Loss of neurons in the nucleus basalis of meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neuropathol 61:101–108
24. Gallagher M, Colombo PJ (1995) Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 5:161–168
25. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399:A23–A31
26. Selkoe DJ (1991) Alzheimer’s disease in the beginning. Nature 354:432–433
27. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733–736
28. Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol 10:373–403
29. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P et al (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571–1577
30. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R et al (2007) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26:134–145
31. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins and therapy. Physiol Rev 81:741–766
32. Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96:11049–11053
33. Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361:260–263
34. Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Ann Rev Pharmacol Toxicol 43:545–584
35. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B et al (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP Gene at the N-terminus of beta-amyloid. Nat Genet 1:345–347
36. Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J et al (1994) Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91:11993–11997
37. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3:16–32
38. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC et al (1998) Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann Neurol 43:380–383
39. Glenner GG, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131–1135
40. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245–4249
41. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791
42. Lane RM, Potkin SG, Enz A (2006) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9:101–124
43. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C et al (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881–891
44. Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL (1999) Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry 38:122–133
45. Barak D, Kronman C, Ordentlich A, Ariel N, Bromberg A, Marcus D et al (1994) Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem 269:6296–6305
46. Wiesner J, Kriz Z, Kuca K, Jun D, Koca J (2007) Acetylcholinesterases-the structural similarities and differences. J Enzyme Inhib Med Chem 22:417–424
47. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM (2013) Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 11:315–335
48. Giacobini E, Mori F, Lai CC (1996) The effect of cholinesterase inhibitors on the secretion of apps from rat brain cortex. Ann N Y Acad Sci 777:393–398
49. Alzheimer’s Association. FDA approved treatments for Alzheimer’s disease. http://www.alz.org/dementia/downloads/topicsheet_treatments.pdf. Accessed 15 Dec 2015
50. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The tacrine study group. JAMA 271:985–991
51. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 3:211–225
52. Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D (2013) Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 70:165–188
53. Mukherjee PK, Kumar V, Mal M, Houghton PJ (2007) Acetylcholinesterase inhibitors from plants. Phytomedicine 14:289–300
54. Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 296:1–8
55. Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1:101–110
56. 2+ in hippocampal slices. Neuropharmacology 38:1253–1259
57. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996) Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 117:689–697
58. Song MS, Rauw G, Baker GB, Kar S (2008) Memantine protects rat cortical cultured neurons against β-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 28:1989–2002
59. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine study group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324
60. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209–221
61. Espinoza-Moraga M, Caballero J, Gaube F, Winckler T, Santos LS (2012) 1-Benzyl-1,2,3,4-tetrahydro-carboline as channel blocker of N-methyl-d-aspartate receptors. Chem Biol Drug Des 79:594–599
62. Gitto R, De Luca L, Ferro S, Ruso E, Sarro GD, Chisari M et al (2014) Synthesis, modeling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors. Bioorg Med Chem 22:1040–1048
63. Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer’s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787–12794
64. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS et al (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet 10:1317–1324
65. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231–232
66. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H (2000) BACE2, a beta- secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 97:9712–9717
67. Benes P, Vetvicka V, Fusek M (2008) Cathepsin D—many functions of one aspartic protease. Crit Rev Oncol Hematol 68:12–28
68. Gruninger-Leitch F, Schlatter D, Küng E, Nelböck P, Dobeli H (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem 277:4687–4693
69. Hong L, Tang J (2004) Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. Biochemistry 43:4689–4695
70. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509
71. Ghosh AK, Gemma S, Tang J (2008) Beta-secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics 5:399–408
72. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA et al (2001) Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 44:2865–2868
73. Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J (2008) Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res 5:121–131
74. John V, Tung J, Fang L, Mamo SS (2000) Statine-derived tetrapeptide inhibitors of beta-secretase. Int. Patent WO2000077030, 2000
75. Peters S, Fuchs K, Eickmeier C, Stransky W, Dorner-Ciossek C, Handschuh S, Nar H, Klinder K, Kostka M (2007) Statine derivatives for the treatment of Alzheimer’s Disease III. US Patent US7238774, 2007
76. Peters S, Fuchs K, Eickmeier C, Stransky W, Dorner-Ciossek C, Handschuh S, Nar H, Klinder K, Kostka M (2006) Statine derivatives for the treatment of Alzheimer’s Disease III. US Patent US20060100158, 2006
77. Peters S, Fuchs K, Eickmeier C, Stransky W, Dorner-Ciossek C, Handschuh S, Nar H, Klinder K, Kostka M (2006) Statine derivatives for the treatment of Alzheimer’s Disease. Int. Patent WO2006050861, 2006
78. Kiso Y (2007) Peptide derivatives having β-secretase inhibitory activity. US Patent US7312188, 2007
79. Kimura T, Shuto D, Hamada Y, Igawa N, Kasai S, Liu P et al (2005) Design and synthesis of highly active Alzheimer’s beta-secretase (BACE1) inhibitors, KMI-420 And KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 15:211–215
80. Wangsell F, Nordeman P, Sävmarker J, Emanuelsson R, Jansson K, Lindberg J et al (2011) Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors. Bioorg Med Chem 19:145–155
81. Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A et al (2006) Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 49:6158–6159
82. Jennings LD, Cole DC, Stock JR, Sukhdeo MN, Ellingboe JW, Cowling R et al (2008) Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1′ substrate binding pocket. Bioorg Med Chem Lett 18:767–771
83. Cole DC, Stock JR, Chopra R, Cowling R, Ellingboe JW, Fan KY et al (2008) Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 18:1063–1066
84. Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RA et al (2007) Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J Med Chem 50:1124–1132
85. Malamas MS, Barnes K, Hui Y, Johnson M, Lovering F, Condon J et al (2010) Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 20:2068–2073
86. Malamas MS, Fobare WF, Solvibile Jr WR, Lovering FE, Condon JS, Robichaud AJ (2006) Amino-pyridines as inhibitors of beta-secretase. US Patent US20060173049, 2006
87. Chiriano G, De Simone A, Mancini F, Perez DI, Cavalli A, Bolognesi ML et al (2012) A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: structure-based design, synthesis, and biological evaluation. Eur J Med Chem 48:206–213
88. Malamas MS, Erdei J, Gunawan I, Barnes K, Johnson M, Hui Y et al (2009) Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem 52:6314–6323
89. Stachel SJ, Steele TG, Petrocchi A, Haugabook SJ, McGaughey G, Katharine Holloway M et al (2012) Discovery of pyrrolidine-based β-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency. Bioorg Med Chem Lett 22:240–244
90. Stachel SJ, Coburn CA, Rush D, Jones KL, Zhu H, Rajapakse H et al (2009) Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1. Bioorg Med Chem Lett 19:2977–2980
91. Hilpert H, Guba W, Woltering TJ, Wostl W, Pinard E, Mauser H et al (2013) β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease. J Med Chem 56:3980–3995
92. Xu W, Chen G, Zhu W, Zuo Z (2010) Molecular docking and structure-activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors. Bioorg Med Chem Lett 20:6203–6207
93. Jeon SY, Bae K, Seong YH, Song KS (2003) Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 13:3905–3908
94. Jeon SY, Kwon SH, Seong YH, Bae K, Hur JM, Lee YY et al (2007) Beta-secretase (BACE1)-inhibiting stilbenoids from Smilax rhizoma. Phytomedicine 14:403–408
95. Marumoto S, Miyazawa M (2010) β-secretase inhibitory effects of furanocoumarins from the root of Angelica dahurica. Phytother Res 24:510–513
96. Marumoto S, Miyazawa M (2012) Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor. Bioorg Med Chem 20:784–788
97. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H (2008) Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 1780:819–825
98. Cho JK, Ryu YB, Curtis-Long MJ, Kim JY, Kim D, Lee S et al (2011) Inhibition and structural reliability of prenylated flavones from the stem bark of Morus ihou on β-secretase (BACE-1). Bioorg Med Chem Lett 21:2945–2948
99. Tao J, Zhao J, Zhao Y, Cui Y, Fang W (2012) BACE inhibitory flavanones from Balanophora involucrata Hook. f. Fitoterapia 83:1386–1390
100. Jung HA, Oh SH, Choi JS (2010) Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett 20:3211–3215
101. Alzforum. Therapeutics LY2886721. http://www.alzforum.org/therapeutics/ly2886721. Accessed 11 Jan 2016
102. Alzforum. Therapeutics Verubecestat. http://www.alzforum.org/therapeutics/verubecestat. Accessed 11 Jan 2016
103. Merck Clinical Trials. An efficacy and safety trial of the investigational drug MK-8931 in mild to moderate Alzheimer’s disease (MK-8931 017). http://www.merck.com/clinical-trials/infographics/P07738. Accessed 11 Jan 2016
104. Astra Zeneca. AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease. https://www.astrazeneca.com/our-company/media-centre/pressreleases/2014/astrazeneca-lilly-bace-inhibitor-azd3293-alzheimers-disease-16092014. Accessed 11 Jan 2016
105. National Institute of Aging. Alzheimer’s Disease Education and Referral Centre. AZD3293 in early Alzheimer’s disease (AMARANTH). https://www.nia.nih.gov/alzheimers/clinical-trials/azd3293-early-alzheimers-disease-amaranth. Accessed 11 Jan 2016
106. ClinicalTrials.gov. A drug-drug interaction study of AZD3293 (LY3314814) in healthy participants. https://clinicaltrials.gov/ct2/show/NCT02406261. Accessed 11 Jan 2016
107. Alzforum. Therapeutics E2609. http://www.alzforum.org/therapeutics/E2609. Accessed 11 Jan 2016
108. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369:341–350
109. Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS et al (2012) BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 51:7209–7211
110. EU Clinical Trials Register. Clinical trials for BMS-708163. https://www.clinicaltrialsregister.eu/ctr-search/search?query=BMS-708163. Accessed 28 Jan 2016
111. Bristol Meyer Squibb. Pipeline Asset Update for BMS-708163 (gamma secretase inhibitor). http://www.bms.com/research/investigational/alzheimers/Pages/BMS708163.aspx. Accessed 28 Jan 2016
112. Coric V, Van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW et al (2012) Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430–1440
113. Coric V, Salloway S, Van Dyck CH, Dubois B, Andreasen N, Brody M et al (2015) Targeting prodromal Alzheimer’s disease with avagacestat: a randomized clinical trial. JAMA Neurol 28:1–10
114. Alzforum. More Evidence that γ-Secretase Modulators Spare Essential Substrates. http://www.alzforum.org/news/research-news/more-evidence-g-secretase-modulators-spare-essential-substrates. Accessed 29 Jan 2016
115. Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T et al (2003) Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces abeta 42 generation. J Biol Chem 278:18664–18670
116. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH (2003) Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) And ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 278:30748–30754
117. Peretto I, La Porta E (2008) Gamma-secretase modulation and its promise for Alzheimer’s disease: a medicinal chemistry perspective. Curr Top Med Chem 8:38–46
118. Galasko D, Graff-Radford N, May S, Hendrix S, Cottrell B, Sagi S et al (2007) Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21:292–299
119. Narlawar R, Pérez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K (2006) Scaffold of the cyclooxygenase-2 (cox-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem 49:7588–7591
120. Hall A, Elliott RL, Giblin GM, Hussain I, Musgrave J, Naylor A et al (2010) Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 20:1306–1311
121. Rivkin A, Ahearn SP, Chichetti SM, Kim YR, Li C, Rosenau A et al (2010) Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 20:1269–1271
122. Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, Garcia Y, Martinez M et al (2010) Purine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 20:2279–2282
123. Findeis MA, Schroeder F, McKee TD, Yager D, Fraering PC, Creaser SP et al (2012) Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea Racemosa. ACS Chem Neurosci 3:941–951
124. Furukawa K, Sopher B, Rydel R, Begley J, Pham D, Martin G et al (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase derived secreted amyloid precursor protein conferred by a C-terminal heparin binding domain. J Neurochem 67:1882–1896
125. Small D, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K et al (1994) A heparin-binding domain in the amyloid protein precursor of Alzheimer’s disease is involved in the regulation of neurite outgrowth. J Neurosci 14:2117–2127
126. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M et al (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96:3922–3927
127. Schmitt U, Hiemke C, Fahrenholz F, Schroeder A (2006) Overexpression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice. Behav Brain Res 175:278–284
128. Bell KFS, Zheng L, Fahrenholz F, Cuello AC (2008) ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging 29:554–565
129. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304–307
130. Robert S, Zugaza J, Fischmeister R, Gardier A, Lezoualc’h F (2001) The human serotonin 5-HT4 receptor regulates secretion of nonamyloidogenic precursor protein. J Biol Chem 276:44881–44888
131. Siopi E, Llufriu-Daben G, Cho AH, Vidal-Lletjos S, Plotkine M, Marchand-Leroux C et al (2013) Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology 67:183–192
132. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R et al (2001) Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 8:28–35
133. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M et al (2007) Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28:537–547
134. Citron M (2004) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9:387–398
135. Aisen P, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P et al (2006) A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67:1757–1763
136. Transition Therapeutics Announces Results of Data Analysis from ELND005 Phase 2/3 Clinical Study in Agitation and Aggression in Alzheimer’s Disease Patients. http://www.prnewswire.com/news-releases/transition-therapeutics-announces-results-of-data-analysis-from-elnd005-phase-23-clinical-study-in-agitation-and-aggression-in-alzheimers-disease-patients-533007951.html. Accessed 9 Feb 2016
137. Hoshino A, Helwig M, Rezaei S, Berridge C, Eriksen JL, Lindberg I (2014) A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer’s disease. J Neurochem 128:419–430
138. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C et al (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 5:452–457
139. Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562
140. Brody D, Holtzman D (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175–193
141. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al (2003) Sub acute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46–54
142. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A et al (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24:198–203
143. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061–2070
144. Alzforum. Therapeutics Rember TM. http://www.alzforum.org/therapeutics/rember-tm. Accessed 12 Feb 2016
145. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS et al (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8:609–622
146. Crowe A, James MJ, Lee VM, Smith AB 3rd, Trojanowski JQ, Ballatore C et al (2013) Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J Biol Chem 288:11024–11037
147. Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM et al (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimers Dis 44:705–720
148. Adis Insight. Drug Profile TRx 0237. http://adisinsight.springer.com/drugs/800034429. Accessed 16 Feb 2016
149. TauRx Therapeutics. http://taurx.com/taurx-005-enrolment.html. Accessed 16 Feb 2016
150. Iqbal K, Grundke-Iqbal I (2007) Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 64:2234–2244
151. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99:1445–1455
152. Engel T, Hernandez F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26:5083–5090
153. Perez M, Hernandez F, Lim F, Díaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5:301–308
154. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH et al (2000) Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7:51–63
155. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM et al (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/P25. Eur J Biochem 267:5983–5994
156. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL et al (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276:251–260
157. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566:261–269
158. PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett 580:3973–3979
159. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J et al (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 107:21830–21835
160. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59:276–289
161. Varjosalo M, Keskitalo S, Van Drogen A, Nurkkala H, Vichalkovski A, Aebersold R et al (2013) The protein interaction landscape of the human CMGC kinase group. Cell Rep 3:1306–1320
162. Guimerá J, Casas C, Pucharcos C, Solans A, Domènech A, Planas AM et al (1996) A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum Mol Genet 5:1305–1310
163. Park J, Song WJ, Chung KC (2009) Function and regulation of DYRK1A: towards understanding Down syndrome. Cell Mol Life Sci 66:3235–3240
164. Wegiel J, Gong CX, Hwang YW (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J 278:236–245
165. Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS et al (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease. J Neurochem 104:1333–1344
166. Ryu YS, Park SY, Jung MS, Yoon SH, Kwen MY, Lee SY et al (2010) DYRK1A mediated phosphorylation of presenilin-1: a functional link between down syndrome and Alzheimer’s disease. J Neurochem 115:574–584
167. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H et al (2007) The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16:15–23
168. Ferrer I, Barrachina M, Puig B, Martínez de Lagrán M, Martí E, Avila J et al (2005) Constitutive DYRK1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 20:392–400
169. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297–315
170. Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I et al (2011) β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer’s disease-related sites. PLoS One 6:e19264
171. Ahmadu A, Abdulkarim A, Grougnet R, Myrianthopoulos V, Tillequin F, Magiatis P et al (2010) Two new peltogynoids from Acacia nilotica delile with kinase inhibitory activity. Planta Med 76:458–460
172. Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199–204
173. Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P et al (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem 54:4172–4186
174. Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E et al (2012) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 55:9312–9330
175. Giraud F, Alves G, Debiton E, Nauton L, Théry V, Durieu E et al (2011) Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. J Med Chem 54:4474–4489
176. Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar Bharate SB (2015) Meridianin derivatives as potent DYRK1A inhibitors and neuroprotective agents. Bioorg Med Chem Lett 25:2948–2952
177. Beniddir MA, Le Borgne E, Iorga BI, Loaec N, Lozach O, Meijer L et al (2014) Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. J Nat Prod 77:1117–1122
178. Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W et al (2009) Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg Med Chem Lett 19:6700–6705
179. Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT et al (2011) Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett 21:3152–3158
180. Ogawa Y, Nonaka Y, Goto T, Ohnishi E, Hiramatsu T, Kii I et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase DYRK1A. Nat Commun 86:1–9
181. Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clément M, Valette A et al (2008) Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 51:737–751
182. Neagoie C, Vedrenne E, Buron F, Mérour JY, Rosca S, Bourg S et al (2012) Synthesis of chromeno [3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. Eur J Med Chem 49:379–396
183. Bruel A, Bénéteau R, Chabanne M, Lozach O, Le Guevel R, Ravache M et al (2014) Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. Bioorg Med Chem Lett 24:5037–5040
184. Sies H (1993) Strategies of antioxidant defense. Eur J Biochem 215:213–219
185. Markesbery WR (1999) The role of oxidative stress in Alzheimer disease. Arch Neurol 56:1449–1452
186. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL et al (1997) Reactive oxygen species and Alzheimer’s disease. Biochem Pharmacol 54:533–539
187. Su JH, Deng G, Cotman CW (1997) Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer’s disease brain. Brain Res 774:193–199
188. Young VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502–511
189. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65:631–641
190. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT et al (2004) Cache county study group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the cache county study. Arch Neurol 61:82–88
191. Bastianetto S, Zheng WH, Quirion R (2000) The Ginkgo biloba extract (Egb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase. J Neurochem 74:2268–2277
192. Behl C, Moosmann B (2002) Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radic Biol Med 33:182–191
193. Forester SC, Lambert JD (2011) Antioxidant effects of green tea. Mol Nutr Food Res 55:844–854
194. Shi C, Liu J, Wu F, Yew DT (2010) Ginkgo biloba extract in Alzheimer’s disease: from action mechanisms to medical practice. Int J Mol Sci 11:107–123
195. Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JS (2009) Anti-Alzheimer and antioxidant activities of Coptidis rhizoma alkaloids. Biol Pharm Bull 32:1433–1438
196. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405
197. Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement S1552–5260:30185–30186
198. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ (2008) Current approaches in the treatment of Alzheimer’s disease. Biomed Pharmacother 62:199–207
199. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P et al (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. Proc Natl Acad Sci USA 103:443–448
200. Wilkinson BL, Cramer PE, Varvel NH, Reed-Geaghan E, Jiang Q, Szabo A et al (2012) Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer’s disease. Neurobiol Aging 33:e21–e32
201. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S et al (2008) Cognitive function over time in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896–905
202. Pettersson M, Kauffman GW, Am Ende CW, Patel NC, Stiff C, Tran TP et al (2011) Novel gamma-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 21:205–226
203. Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS (2015) Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol 38:243–250
204. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627–1631
205. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW et al (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74:956–964
206. McGuinness B, O’Hare J, Craig D, Bullock R, Malouf R, Passmore P (2010) Statins for the treatment of dementia. Cochrane Database Syst Rev 8:CD007514